Vertex Pharmaceuticals: Kursziel gesenkt
London (www.aktiencheck.de) - Rating-Update:
Gena Wang, Analystin von Barclays, stuft die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN 882807, Ticker-Symbol:…
Börse:
193,001$
-10,96%
Echtzeit-Aktienkurs Vertex Pharmaceuticals
Bid:
192,630$
Ask:
193,372$
Nachrichten zur Vertex Pharmaceuticals Aktie
Vertex Pharmaceuticals: Kursziel nach unten revidiert
St. Louis (www.aktiencheck.de) - Rating-Update:
Paul Matteis, Analyst von Stifel, stuft die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN…
Vertex Pharmaceuticals: Kursziel reduziert
New York (www.aktiencheck.de) - Rating-Update:
Alethia Young, Analystin von Cantor Fitzgerald, stuft die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN…
What 11 Analyst Ratings Have To Say About Vertex Pharmaceuticals
Analysts have provided the following ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) within the last quarter:
Latest Ratings for VRTX
…
Vertex (VRTX) Ends Further Study on AAT Deficiency Candidate
Vertex (VRTX) to discontinue further development of AATD candidate, VX-864, as it appears unlikely to benefit patients....…
Vertex Pharmaceuticals: Kurszielsenkung
Toronto (www.aktiencheck.de) - Rating-Update:
Brian Abrahams, Analyst vom Investmenthaus RBC Capital Markets, stuft die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003,…
Why Vertex Pharmaceuticals Stock Is Getting Hammered Today
Another clinical setback isnt sitting well with shareholders today....…
Biogen Gains, Vertex Pharmaceuticals Drops, and the Stock Market Keeps Rising
Stocks look set for a higher open as a bipartisan group of senators reached an infrastructure deal....…
Vertex Pharmaceuticals stock tumbles to pace S&P 500 losers after disappointing drug trial data
Shares of Vertex Pharmaceuticals Inc. tumbled 13.8% in premarket trading Friday, enough to pace the S&P 500's early…
Vertex Pharmaceuticals: Downgrade
Tokio (www.aktiencheck.de) - Rating-Update:
Narumi Nakagiri von Daiwa Capital Markets senkt die Anlageempfehlung für die Aktie von Vertex Pharmaceuticals Inc. (ISIN:…
10 Biggest Price Target Changes For Friday
Barclays lowered Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) price target from $302 to $285. Vertex Pharmaceuticals shares fell 13.3% to…
Stocks making the biggest moves in the premarket: Snowflake, Vertex Pharmaceuticals, Chewy & more
The stocks making the biggest moves in premarket trading include Snowflake, Vertex Pharmaceuticals, Chewy, and more....…
Vertex Pharmaceuticals Seen as Buying Opportunity as Stock Plunges
Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…
Despite Hitting Mid-Stage Trial Endpoint Goal, Vertex Strikes Out Rare Lung Disease Candidate; Stock Tumbles
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced the Phase 2 data evaluating VX-864 in alpha-1 antitrypsin deficiency (AATD) with the PiZZ genotype.
read…
Vertex Pharmaceuticals: "overweight"
Minneapolis (www.aktiencheck.de) - Rating-Update:
Edward Tenthoff, Analyst von Piper Sandler, stuft die Aktie des US-Biotechkonzerns Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN…
Vertex Pharmaceuticals: Zweistelliger Kursrutsch! Aktienanalyse
Kulmbach (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von "Der Aktionär":
Michel Doepke, Redakteur beim Anlegermagazin "Der Aktionär", nimmt in einer aktuellen Aktienanalyse die…
Vertex-Aktie massiv unter Beschuss: Das ist der Grund
Die Biotech-Gesellschaft Vertex Pharmaceuticals hat die Behandlung der Stoffwechselerkrankung Mukoviszidose (auch bekannt als Zystische Fibrose) revolutioniert. Doch mit dem Abbruch…
Vertex Pharmaceuticals Nabs Key FDA Approval in Cystic Fibrosis
The Food and Drug Administration has expanded eligibility for Trikafta to include amenable cystic fibrosis patients aged 6 to 11....…
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $209.16, marking a -0.37% move from the previous day....…
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $209.93, moving -0.58% from the previous trading session....…
Is Vertex Pharmaceuticals a Buy?
This biotechs growth has stalled. Should you give its stock a chance?...…
Insiderhandel: EVP, Chief Patient Officer verkauft Aktien von Vertex Pharmaceuticals im Wert von 9.736$
Sachdev, Amit - Vorstand - Tag der Transaktion: 2021-05-17...…
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $215.01, marking a +0.87% move from the previous day....…
Biotech Report: Biontech (22UA) und Evotec (EVT) ziehen an; Qiagen (QIA) leicht unter Druck
Biotech-Werte zeigen sich im deutschen Handel überwiegend fester. Für Biontech und Evotec geht es aufwärts, während Qiagen unter Druck…
VERTEX PHARMACEUTICALS INC / MA: 10-Q Report
10-Q...…
Vertex Pharmaceuticals Incorporated 2021 Q1 - Results - Earnings Call Presentation
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Vertex Pharmaceuticals Incorporated (VRTX) CEO Dr. Reshma Kewalramani on Q1 2021 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Vertex Pharmaceuticals Inc (VRTX) Q1 2021 Earnings Call Transcript
VRTX earnings call for the period ending March 31, 2021....…
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Surpass Estimates
Vertex (VRTX) delivered earnings and revenue surprises of 7.58% and 3.87%, respectively, for the quarter ended March 2021. Do the…
Vertex Pharmaceuticals Inc. Q1 adjusted earnings Beat Estimates
CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) reported earnings for its first quarter that increased from the same period…
Vertex Pharmaceuticals EPS beats by $0.29, beats on revenue
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Vertex: NaV1.8-Inhibitor erreicht Phase 2 der klinischen Entwicklung
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) wird die klinische Entwicklung des selektiven NaV1.8-Inhibitors VX-548 in die Phase 2 überführen und…
Why CRISPR Therapeutics Stock Is Trading Higher Today
CRISPR Therapeutics (NASDAQ: CRSP) shares are trading higher after the company and its partner Vertex Pharmaceuticals announced the EMA granted…
Is Vertex Pharmaceuticals a Good Stock to Buy Right Now?
See if the formerly high-flying biotech deserves a place in your portfolio....…
Vertex and Obsidian partner to discover gene-editing medicines
Vertex Pharmaceuticals and Obsidian Therapeutics have established a multi-year collaboration for the discovery of new treatments that regulate gene editing.…
Vertex Pharma Inks Research, Licensing Agreement With Obsidian Therapeutics For Controllable Genetic Therapies
read more...…
Vertex Pharma, Obsidian Announce Research Collaboration And Licensing Agreement
CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Incorporated (VRTX) and Obsidian Therapeutics have entered a research collaboration and licensing agreement, under…
Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership
Vertex (VRTX) to lead CRISPR Therapeutics for manufacture and commercialization of gene-editing therapy CTX001 which is being developed for treating…
Vertex to study experimental gene-editing therapy as treatment for sickle cell, beta-thalassemia
Vertex Pharmaceuticals Inc. said Tuesday it plans to pay $1.1 billion to Crispr Therapeutics AG as part of…
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $220.16, marking a +0.45% move from the previous day....…
Vertex Pharmaceuticals Raises Bet on CRISPR Therapeutics
The amended collaboration agreement comes with a big up-front payment....…
VERTEX PHARMACEUTICALS INC / MA: 8-K Report
8-K...…
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia
- Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001-...…
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
Vertex Pharmaceuticals (VRTX) closed at $217.13 in the latest trading session, marking a +0.55% move from the prior day....…
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $211.54, moving -0.96% from the previous trading session....…
The Zacks Analyst Blog Highlights: Abbott Laboratories, AstraZeneca, Booking, Vertex Pharmaceuticals and Yum China
The Zacks Analyst Blog Highlights: Abbott Laboratories, AstraZeneca, Booking, Vertex Pharmaceuticals and Yum China...…
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
Vertex Pharmaceuticals (VRTX) closed at $215.15 in the latest trading session, marking a +0.4% move from the prior day....…
Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins
Vertex (VRTX) begins early-stage clinical study on cellular therapy, VX-880 for type-I diabetes. FDA also grants Fast Track status to…
Vertex gibt Erteilung des Fast-Track-Status durch die FDA und Start der klinischen Phase-1/2-Studie zu VX-880 bekannt – eine neuartige Zelltherapie zur Behandlung von Typ-1-Diabetes
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) gab heute bekannt, dass die US-amerikanische Arzneimittelaufsichtsbehörde FDA (Food and Drug Administration) VX-880 den…
Vertex to begin Phase 1/2 trial of treatment for people with type 1 diabetes
Shares of Vertex Pharmaceuticals Inc. were down 0.2% in trading on Wednesday after the company said it started an…